Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Shares Outstanding (Diluted Average) (2021 - 2025)

Rani Therapeutics Holdings has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $66138.0 for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $66138.0 for Q4 2025, up 132.26% from a year ago — trailing twelve months through Dec 2025 was $66138.0 (up 132.26% YoY), and the annual figure for FY2025 was $66138.0, up 132.26%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $66138.0 at Rani Therapeutics Holdings, down from $38.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for RANI hit a ceiling of $38.9 million in Q3 2025 and a floor of $19534.0 in Q4 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $24.3 million (2022), compared with a mean of $19.6 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 3.15% in 2024 and later skyrocketed 132.26% in 2025.
  • Rani Therapeutics Holdings' Shares Outstanding (Diluted Average) stood at $19534.0 in 2021, then increased by 21.93% to $23817.0 in 2022, then increased by 7.09% to $25505.0 in 2023, then increased by 11.65% to $28476.0 in 2024, then soared by 132.26% to $66138.0 in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $66138.0 (Q4 2025), $38.9 million (Q3 2025), and $35.0 million (Q2 2025) per Business Quant data.